BiodesixBDSX
Recorded

Biodesix 2026 UBS Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration33 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

All right. Good afternoon. My name is Doug Schenkel. On behalf of UBS, it is my pleasure to welcome Robyn Cowie, Chief Financial Officer, and Tim Dupont, Head of Sales Operations and Project Manager, as well as leader for digital diagnostic development at Biodesix. Thanks to the two of you for joining us this afternoon.

Tyler DuPontHead of Sales Operations and Project Manager

Thanks for having us. It is our pleasure, Doug.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

Thanks. So, over the next half hour, there are a few things we want to talk about.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

Most importantly, we want to talk about Nodify adoption, commercial execution, the financial model, and since we have you here, Tim, we want to take advantage and dig in on digital diagnostics. In terms of the roadmap, we will start with the patient pathway, we will get into sales operations, we will talk about commercial, and then, as I said, we will get into digital. So, Nodify, for those of you who do not know the company, and I will take a shot, and if I am messing anything up, please clean up for me. So this is a blood-based nodule risk assessment tool. Nodify CDT flags likely malignancy. Nodify XL2 identifies likely benign nodules. And there are, what is it, about 1.6 million U.S. patients who have incidental nodules identified annually. So, it is a big opportunity.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

Clean up for me if I am messing anything up.

Robin Harper CowieCFO

Yeah, there is actually a lot more now. So that number is almost 15 years old.

Robin Harper CowieCFO

Yeah, is that right? The current estimates are 5 million-6 million annually in the U.S.

Robin Harper CowieCFO

So a massive problem in our healthcare system.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

Yep. Yep. All right, we got the products, we got the opportunity. In the third quarter, diagnostic testing was $23 million, up 16% year-over-year. You did 19,400 tests, up 24%. You are expected to do, I think, still over $100 million for the year.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

Yeah, correct. So 15% at the midpoint.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

That being said, good growth, big opportunity. To just do a quick Q3 recap, maybe just starting with the obvious question, because you did come up a little bit light of expectations. How confident are you that the third quarter shortfall was transitory rather than something more than that?

Robin Harper CowieCFO

Yeah, that is obviously the most important question. We spent a lot of time once the trends mid to late quarter started to become apparent, really diving in to understand what was happening across the business, what we were seeing, to make some changes and interventions and to ensure that we are seeing results from those changes. We are happy to report that October was our strongest month of new physician acquisition. We saw our base customer ordering patterns improve in October, and so we are feeling good about the changes we have made and how that is rebounding.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

Some of this is, I mean, just to push a little bit more, there were some changes in the number of the street from a sales rep standpoint. That is part of this, right?

Robin Harper CowieCFO

That is a big driver, yeah.

Doug SchenkelAmericas Head of Diversified Healthcare and Life Science and Diagnostics Tools Research Analyst

Okay. I thought you guys said something like there was greater-than-expected primary care seasonality.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day